Abstract 670P
Background
Tinengotinib is a spectrum-selective multi-kinase inhibitor that targets cell proliferation, angiogenesis, and immune-oncology pathways by inhibiting Aurora kinases A/B, Janus kinases and receptor tyrosine kinases (FGFRs and VEGFRs). Tinengotinib has shown promising clinical signal in solid tumors from several studies globally. Here we present the interim data from a phase Ib/II trial in China.
Methods
Pts with advanced/metastatic solid tumors were enrolled and treated with tinengotinib in 21-day cycle. Monotherapy and combination therapy with dose escalation (phase Ib) and dose expansion (phase II) were designed.
Results
As of 5-Mar-2023, thirty-three (33) pts have received tinengotinib monotherapy. Median age was 58.0 years (29-81), 66.7% were male, 81.8% had ECOG of 1, 87.9% had stage IV disease, 69.7% had ≥3 lines of prior therapies. No DLT was observed in phase Ib (3 pts in each group of 8, 10, 12 mg QD). 10 mg QD was selected as RP2D. Treatment-related AEs (TRAEs) were reported in 30 (90.9%) pts, Gr 3 in 14 (42.4%), Gr 4 in 1 (3.0%), and no Gr 5. The most common TRAEs (≥30%) included abnormal laboratory parameters (blood thyroid stimulating hormone increased, white blood cell count decreased, neutrophil count decreased, aspartate aminotransferase increased, alanine aminotransferase increased), palmar-plantar erythrodysaesthesia syndrome and anaemia. Among 22 efficacy-evaluable pts, the median Progression-free survival (PFS) have reached 6.70 (95% CI, 3.22-NA) months. For 19 pts with measurable target lesions, the overall response rate (ORR) and disease control rate (DCR) were 15.8% and 89.5%, respectively. For 4 CCA pts harboring FGFR2 alteration, ORR was 50%, DCR was 100%. One responder with prior treatment of erdafitinib achieved tumor reduction of 44%, the other with no prior FGFR inhibitor treatment achieved 69% reduction.
Conclusions
Tinengotinib monotherapy was well-tolerated in Chinese pts and 10 mg QD was selected as RP2D. Promising efficacy has been observed, especially in CCA with FGFR2 alteration. The ongoing study is to further evaluate the safety and efficacy of monotherapy and combination therapy.
Clinical trial identification
NCT05253053.
Editorial acknowledgement
Legal entity responsible for the study
TransThera Sciences (Nanjing), Inc.
Funding
TransThera Sciences (Nanjing), Inc.
Disclosure
J. Fan: Financial Interests, Personal, Officer, I am Chief Medical Officer, full time employee at TransThera Sciences, Inc.: TransThera Sciences, Inc.; Financial Interests, Personal, Stocks/Shares, I owned AstraZeneca's stocks: AstraZeneca; Non-Financial Interests, Member: ASCO, ESMO, AACR. L. Shen: Financial Interests, Personal, Other, Consulting fees: Mingji biopharmaceutical, Haichuang pharmaceutical, Herbour biomed; Financial Interests, Personal, Advisory Board: MSD, Merck, BMS, BI, Sanofi, Roche, Servier, AZ; Financial Interests, Institutional, Funding: Beijing Xiantong Biomedical Technology, Qilu Pharmaceutical, ZaiLab Pharmaceutical (Shanghai), Alphamab Oncology, Yaojie Ankang (Nanjing) Technology Co., Ltd., BeiGene, Ltd., Qiyu Biotechnology (Shanghai) Co., Ltd., BriSTAR Immunotech; Financial Interests, Institutional, Local PI: Merck Healthcare KGaA, Roche; Financial Interests, Institutional, Trial Chair: Rongchang Pharmaceutical, Innovent, BeiGene, Ltd., Qilu Pharmaceutical, NovaRock Biotherapeutics Limited. All other authors have declared no conflicts of interest.
Resources from the same session
668P - Efficacy and safety of larotrectinib in a pooled analysis of patients (Pts) with tropomyosin receptor kinase (TRK) fusion cancer
Presenter: Alexander Drilon
Session: Poster session 17
669P - Patient-reported outcomes with selpercatinib in patients with RET-driven cancers in the phase I/II LIBRETTO-001 trial
Presenter: Hyunseok Kang
Session: Poster session 17
671P - Safety and efficacy of PM060184 plus gemcitabine in advanced solid tumors
Presenter: Sanjay Goel
Session: Poster session 17
672P - Phase I/II trial of RVU120 (SEL120), CDK8/CDK19 inhibitor in patients with relapsed/refractory metastatic or advanced solid tumors
Presenter: Rafal Dziadziuszko
Session: Poster session 17
673P - A phase I dose-escalation and expansion study evaluating the safety and efficacy of the MDM2–p53 antagonist brigimadlin (BI 907828) in patients (pts) with solid tumours
Presenter: Patrick Schoeffski
Session: Poster session 17
674P - Response of thrombopoietin receptor agonists in MDM2 inhibitor induced thrombocytopenia
Presenter: Raymond DeMatteo
Session: Poster session 17
675P - A phase I study of safety, pharmacokinetics, and pharmacodynamics of SCR-6920, a protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced malignant tumors
Presenter: Jinming Yu
Session: Poster session 17
676P - Preclinical characterization of novel peptide binders for EphA2-targeted radiopharmaceutical therapy
Presenter: Renee Clift
Session: Poster session 17
677P - Preliminary findings from a phase I, open-label, dose-finding study of SNB-101 in patients with advanced solid tumors
Presenter: Yun Beom Sang
Session: Poster session 17
678P - ExoDS: A bioengineered exosome-based capsule for targeted delivery of chemotherapy drugs to cancer cells and cancer stem cells
Presenter: Abhishek Dutta
Session: Poster session 17